The development of the vaccine against Covid-19 from the company Hipra enters its final phase. The last tests of this antigen will be carried out in centers of the group HM Hospitalsin addition to different public hospitals, as confirmed by the pharmacist to this newspaper.
We will still have to wait for the approval of the Spanish Agency for Medicines and Health Products (AEMPS) for it to start up the third and final phase of the clinical trial of the Spanish vaccine.
As confirmed by the company, the participation of the HM Hospitals group It is in the absence of “finalizing the agreement”. “It will be soon,” they add.
Hipra’s drug has become the great hope for Spanish science after what was until then the first vaccine prototype, the one developed by Mariano Esteban’s team at the National Center for Biotecnologia (CNB-CSIC) together with Biofabri after the death of a macaque.
This is Hipra’s anti-Covid vaccine
PHH-1V, which is the name of the vaccine at the moment, is based on a technology that is different from that used by current preparations against Covid, although it is well known. Instead of introducing messenger RNA so that the cells themselves make the SARS-CoV-2 S protein (the one used by the virus to infect the body) or to do it through a different inactivated virus (such as those from AstraZeneca or Janssen) , what it contains is directly that synthesized protein.
This protein is made up of two subunits based on the alpha and beta variants of the virus, plus a third molecule that acts as penhancer in the manufacture of antibodies. Therefore, the translation of the genetic information into a protein that is recognized by the immune system is carried out outside the human body, in cell cultures that are then purified to extract the serum from them.
In addition, the vaccine that Hipra is developing has presented good results against the omicron variant, according to the Minister of Science and Innovation, Diana Morant, on January 4.
“The results and the resistance presented by the vaccine that is being tested today against the new variant, against the omicron, have just told me that it isgood“, indicated the minister, who hopes that it will be marketed in the second quarter of this year.
If the clinical trials come to fruition, the company’s initial forecasts are to produce 400 million doses during the year 2022. By 2023, 1.2 billion vaccines could be reached.